📊 WHWK Key Takeaways
Is Whitehawk Therapeutics, Inc. (WHWK) a Good Investment?
Whitehawk Therapeutics is a pharmaceutical company in severe financial distress with accelerating revenue collapse (-72.5% YoY to $7.1M) while burning $98M annually in free cash flow. With only $37.6M cash on hand, the company has less than 5 months of operational runway at current burn rates, making it at high risk of equity dilution or insolvency despite holding a balance sheet with minimal debt.
Why Buy Whitehawk Therapeutics, Inc. Stock? WHWK Key Strengths
- Zero long-term debt with clean balance sheet
- Excellent liquidity metrics (10.26x current and quick ratios)
- Stockholders' equity of $136.3M exceeds liabilities 9x
WHWK Stock Risks: Whitehawk Therapeutics, Inc. Investment Risks
- Catastrophic cash burn of -$98M FCF with only $37.6M cash runway (4-5 months)
- Revenue collapsed 72.5% YoY indicating failed commercialization or pipeline failure
- Operating losses of -$114.4M on minimal $7.1M revenue suggests broken business model
- Biotech/pharma company with no meaningful revenue generation or path to profitability
- Will require significant capital raise or restructuring within months
Key Metrics to Watch
- Quarterly cash burn rate and remaining cash balance (critical runway analysis)
- Revenue trend (any stabilization or further decline)
- Operating cash flow trajectory (indicates sustainability)
- Form 4 insider activity patterns (potential dilutive equity issuance signals)
Whitehawk Therapeutics, Inc. (WHWK) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 10.26x current ratio provides a solid financial cushion.
WHWK Profit Margin, ROE & Profitability Analysis
WHWK vs Healthcare Sector: How Whitehawk Therapeutics, Inc. Compares
How Whitehawk Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Whitehawk Therapeutics, Inc. Stock Overvalued? WHWK Valuation Analysis 2026
Based on fundamental analysis, Whitehawk Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Whitehawk Therapeutics, Inc. Balance Sheet: WHWK Debt, Cash & Liquidity
WHWK Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Whitehawk Therapeutics, Inc.'s revenue has grown significantly by 78% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.36 indicates the company is currently unprofitable.
WHWK Revenue Growth, EPS Growth & YoY Performance
WHWK Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $2.7M | $0.04 |
| Q2 2025 | N/A | -$14.6M | $0.37 |
| Q1 2025 | $5.4M | -$18.3M | $-0.68 |
| Q3 2024 | $6.0M | -$12.5M | $-0.46 |
| Q2 2024 | $6.2M | -$14.6M | $-0.54 |
| Q1 2024 | $5.4M | -$15.2M | $-0.57 |
| Q3 2023 | $4.2M | -$13.9M | $-0.60 |
| Q2 2023 | $3.4M | -$13.9M | $-0.67 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Whitehawk Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
WHWK SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Whitehawk Therapeutics, Inc. (CIK: 0001422142)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 17, 2026 | 4 | xslF345X06/form4-04172026_080413.xml | View → |
| Apr 15, 2026 | 4 | xslF345X06/form4-04152026_110455.xml | View → |
| Apr 13, 2026 | 4 | xslF345X06/form4-04142026_120420.xml | View → |
| Apr 10, 2026 | 4 | xslF345X06/form4-04102026_100459.xml | View → |
| Apr 8, 2026 | 4 | xslF345X06/form4-04092026_120451.xml | View → |
❓ Frequently Asked Questions about WHWK
What is the AI rating for WHWK?
Whitehawk Therapeutics, Inc. (WHWK) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are WHWK's key strengths?
Claude: Zero long-term debt with clean balance sheet. Excellent liquidity metrics (10.26x current and quick ratios).
What are the risks of investing in WHWK?
Claude: Catastrophic cash burn of -$98M FCF with only $37.6M cash runway (4-5 months). Revenue collapsed 72.5% YoY indicating failed commercialization or pipeline failure.
What is WHWK's revenue and growth?
Whitehawk Therapeutics, Inc. reported revenue of $7.1M.
Does WHWK pay dividends?
Whitehawk Therapeutics, Inc. does not currently pay dividends.
Where can I find WHWK SEC filings?
Official SEC filings for Whitehawk Therapeutics, Inc. (CIK: 0001422142) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is WHWK's EPS?
Whitehawk Therapeutics, Inc. has a diluted EPS of $-0.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is WHWK a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Whitehawk Therapeutics, Inc. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is WHWK stock overvalued or undervalued?
Valuation metrics for WHWK: ROE of -15.1% (sector avg: 15%), net margin of -288.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy WHWK stock in 2026?
Our dual AI analysis gives Whitehawk Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is WHWK's free cash flow?
Whitehawk Therapeutics, Inc.'s operating cash flow is $-97.4M, with capital expenditures of $552.0K. FCF margin is -1,371.4%.
How does WHWK compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -288.3% (avg: 12%), ROE -15.1% (avg: 15%), current ratio 10.26 (avg: 2).